Key Metrics
CiteScore 

9.6
H-Index 

147
Impact Factor 

5 - 10
SJR 

Q1Neurology

SNIP 

1.52
Recommended pre-submission checks
Powered by 

Topics Covered on Multiple Sclerosis Journal
Multiple Sclerosis Journal Journal Specifications
| Overview | |
| Publisher | SAGE PUBLICATIONS LTD |
| Language | English |
| Frequency | Monthly |
| General Details | |
| Language | English |
| Frequency | Monthly |
| Publication Start Year | 1995 |
| Publisher URL | Visit website |
| Website URL | Visit website |
View less
Planning to publish in Multiple Sclerosis Journal ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations

Recently Published Papers in Multiple Sclerosis Journal
ACTRIMS Forum 2026.
- 1 May 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)
Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab.
- 26 Apr 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS: YES.
- 26 Apr 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS? Commentary.
- 26 Apr 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)
Utility, validity, feasibility and acceptability of a clinician-administered depression, two-question screening tool for routine multiple sclerosis clinic administration.
- 26 Apr 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS? No.
- 26 Apr 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)
ACTRIMS Forum 2026.
- 1 May 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)
Cladribine in multiple sclerosis with autoimmune comorbidities: Further clinical insights from patients with rheumatologic disease treated in combination with secukinumab.
- 26 Apr 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS: YES.
- 26 Apr 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS? Commentary.
- 26 Apr 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)
Utility, validity, feasibility and acceptability of a clinician-administered depression, two-question screening tool for routine multiple sclerosis clinic administration.
- 26 Apr 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)
Should autologous HSCT be a first-line option in highly active MS? No.
- 26 Apr 2026
- Multiple sclerosis (Houndmills, Basingstoke, England)